TACE/ADAM17 Is Essential for Oligodendrocyte Development and CNS Myelination
- Javier Palazuelos1,
- Howard C. Crawford2,
- Michael Klingener1,
- Bingru Sun1,
- Jason Karelis1,
- Elaine W. Raines3, and
- Adan Aguirre1
- 1Department of Pharmacological Sciences, Centers for Molecular Medicine, Stony Brook University, SUNY, New York 11794,
- 2Mayo Clinic Cancer Center, Jacksonville, Florida 32224, and
- 3Department of Pathology, University of Washington, Seattle, Washington 98195
-
Author contributions: J.P. and A.A. designed research; J.P., M.K., B.S., J.K., and A.A. performed research; H.C.C. and E.W.R. contributed unpublished reagents/analytic tools; J.P., M.K., and A.A. analyzed data; J.P. and A.A. wrote the paper.
Abstract
Several studies have elucidated the significance of a disintegrin and metalloproteinase proteins (ADAMs) in PNS myelination, but there is no evidence if they also play a role in oligodendrogenesis and CNS myelination. Our study identifies ADAM17, also called tumor necrosis factor-α converting enzyme (TACE), as a novel key modulator of oligodendrocyte (OL) development and CNS myelination. Genetic deletion of TACE in oligodendrocyte progenitor cells (OPs) induces premature cell cycle exit and reduces OL cell survival during postnatal myelination of the subcortical white matter (SCWM). These cellular and molecular changes lead to deficits in SCWM myelination and motor behavior. Mechanistically, TACE regulates oligodendrogenesis by modulating the shedding of EGFR ligands TGFα and HB-EGF and, consequently, EGFR signaling activation in OL lineage cells. Constitutive TACE depletion in OPs in vivo leads to similar alterations in CNS myelination and motor behavior as to what is observed in the EGFR hypofunctional mouse line EgfrWa2. EGFR overexpression in TACE-deficient OPs restores OL survival and development. Our study reveals an essential function of TACE in oligodendrogenesis, and demonstrates how this molecule modulates EGFR signaling activation to regulate postnatal CNS myelination.
- Received March 17, 2014.
- Revision received June 18, 2014.
- Accepted July 3, 2014.
- Copyright © 2014 the authors 0270-6474/14/3411884-13$15.00/0





